Skip to content

Study on the safety and efficacy of cypofol combined with Dezocine for gastroenteroscopy in obese patients

Study on the safety and efficacy of cypofol combined with Dezocine for gastroenteroscopy in obese patients

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073428
Enrollment
Unknown
Registered
2023-07-11
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases that require a gastroenteroscopy

Interventions

Propofol group (group B) :Slowly inject propofol 2 0 mg/kg until the patient falls asleep

Sponsors

Shunde Hospital of Southern Medical University(The First People's Hospital of Shunde)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old, =80 years old, gender unlimited 2. Patients receiving selective gastroenteroscopy 3. ASA grade I or II 4. BMI=30kg/m2 5. The operation time of gastroenteroscopy is expected to be no more than 30min 6: 6. Clearly understand and voluntarily participate in the study, and have their own or their family members sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Complex endoscopic diagnosis and treatment techniques need to be performed (such as cholangiopancreatography, endoscopic endoscopy, endoscopic mucosal resection, endoscopic submucosal dissection, oral endoscopic muscle dissection, etc.) 2. Patients to be intubated 3. SpO2=95% after entry 4. A definite disgnosis of sleep apnea syndrome 5. Weight 2 units of alcohol (1 unit =360mL beer or 45mL liquor with 40% alcohol or 150mL wine) 14. Patients with craniocerebral injury, possible history of convulsion, myoclonus, intracranial hypertension, brain aneurysm, cerebrovascular accident Patients with schizophrenia, intellectual disability, mania, insanity, long-term use of psychotropic drugs, drug addiction, cognitive dysfunction, etc. 15.The investigator considers the patients unfit to participate in this study.

Design outcomes

Primary

MeasureTime frame
Induced sedation onset time;Gastroenteroscopy time;awakening time;Directional force recovery time;Total dosage of sedative drugs;Overall adverse event rate;

Countries

China

Contacts

Public ContactYanjing Zhang

Shunde Hospital of Southern Medical University(The First People's Hospital of Shunde)

1148644826@qq.com+86 181 2480 9796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026